Oncology

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3832-3839
DOI: 10.26355/eurrev_202206_28950

Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients

C. Peng, C. Juan, W. Mao, Y. Jinghe, T. Renli
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3827-3831
DOI: 10.26355/eurrev_202206_28949

Extranodal NK/T-cell lymphoma: a case report of renal insufficiency during PD1 inhibitor treatment

H.-Y. Hu, X.-X. Xie, S.-T. Tan, X. Fan, J. He
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3807-3826
DOI: 10.26355/eurrev_202206_28948

Construction of a hypoxic immune microenvironment associated gene-based model for prognosis prediction of lung adenocarcinoma

G.-Y. Lin, S. Wu, Z.-S. Gao, L.-H. Wu, J.-J. Yan, X.-Q. Guo, Z.-Y. Wang
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3800-3806
DOI: 10.26355/eurrev_202206_28947

LncRNA H19 inhibits proliferation and enhances apoptosis of nephroblastoma cells by regulating the miR-675/TGFBI axis

H.-C. Liu, W.-Y. Zhu, L.-Y. Ren
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3799-3799
DOI: 10.26355/eurrev_202206_28946

MiR-466 as a poor prognostic predictor suppresses cell proliferation and EMT in breast cancer cells by targeting PSMA7

Y. Xiao, S.-J. Zhang, X. Yan, C. Wu, Q.-W. Liu, H.-X. Dong, L.-J. Wang, Y. Hu
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (11): 3798-3798
DOI: 10.26355/eurrev_202206_28945

Circ_0005276 aggravates the development of epithelial ovarian cancer by targeting ADAM9

Z.-H. Liu, W.-J. Liu, X.-Y. Yu, X.-L. Qi, C.-C. Sun
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3585-3592
DOI: 10.26355/eurrev_202205_28854

The role of fetal programming in human carcinogenesis – May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression?

F. Coghe, D. Fanni, C. Gerosa, A. Ravarino, M. Mureddu, G. Cerrone, P. Coni, G. Pichiri, T. Congiu, M. Piras, F. Cau, V. Aimola, A. Balestrieri, E. Lai, M. Manchia, A. Scano, G. Orrù, G. La Nasa, P. Van Eyken, L. Saba, M. Scartozzi, M. Castagnola, G. Faa
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3577-3584
DOI: 10.26355/eurrev_202205_28853

Discrimination between glioblastoma and solitary brain metastasis: a quantitative analysis based on FLAIR signal intensity

D.-H. Nguyen, D.-M. Nguyen, H.-V. Nguyen, V.-A. Nguyen-Thi, H.-A. Nguyen-Thi, T.-X. Nguyen, M.-D. Nguyen
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3570-3576
DOI: 10.26355/eurrev_202205_28852

A short review on cervical cancer cell lines characterization and their corresponding human leukocyte antigen (HLA) type expression

R.S. Rajan, S.A. Dass, G.J. Tye, V. Balakrishnan
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3562-3569
DOI: 10.26355/eurrev_202205_28851

Investigation on the prevalence of thyroid cancer in Graves’ patients in northeastern part of Turkey: is surgery a better option for patients with Graves’ disease who develop antithyroid drug-related major adverse events?

R. Dayanan, A. Bilen, T. Demirci, S. Ciftel, E. Ciftel, F. Mercantepe, E. Onalan, İ. Capoglu, H. Bilen
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3551-3561
DOI: 10.26355/eurrev_202205_28850

A bibliometric analysis for relapsed/refractory Non-Hodgkin lymphoma

F.-P. Zhang, X.-Y. Zhao, J. Zhou, L.-K. Liu, J.-Z. Bao, Y.-M. Zhou
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3544-3550
DOI: 10.26355/eurrev_202205_28849

Expression of ER, PR, HER2, and Cadherin tumor markers in a series of Saudi patients with BC

H.G. Ahmed, A.B. Mohammed El Hag, K.K. Alanazi, H.M. Alkwai, A.M. Ahmed Abdrhman, A.O. Ahmed Hassan, I.A. Mohamed Ginawi, A.M. Elasbali, H. Sherfi
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3534-3543
DOI: 10.26355/eurrev_202205_28848

Predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET/CT

F. Aras, A. Olmezoglu
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3522-3533
DOI: 10.26355/eurrev_202205_28847

Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials

X.-Y. Lan, D. Li, S. Li, L.-Z. Zhong, H. Zhao, Y.-L. Xi, Z.-W. Sun
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3514-3521
DOI: 10.26355/eurrev_202205_28846

CircRIP2 aggravates the deterioration of colorectal carcinoma by negatively regulating CBFB

M. Hou, L.-J. Zhang, J. Liu, H.-X. Hu, Y.-L. Zhao
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (10): 3406-3406
DOI: 10.26355/eurrev_202205_28830

HOXA13 upregulation in gastric cancer is associated with enhanced cancer cell invasion and epithelial-to-mesenchymal transition

Y.-X. He, X.-H. Song, Z.-Y. Zhao, H. Zhao
Free PDF Download

Eur Rev Med Pharmacol Sci 2022; 26 (9): 3100-3108
DOI: 10.26355/eurrev_202205_28727